This year’s Eric D. Hadar Distinguished Lecturer, Dr. Rajita Sinha, will present “Can We Rescue Stress and Trauma Related Pathophysiology in Addiction to Improve Treatment Outcomes?” on Nov. 16, 2022.
“As we treat more people with ketamine, an unfortunate side effect of that is more exposure, which means that we're going to create more ketamine addicts,” said Dr. Drew Ramsey.
Dr. J. John Mann says while there are clear short-term benefits to ketamine, its long-term effects, its abuse potential and the optimal number of treatments a patient should receive are still unknown.
Columbia Psychiatrists suggest that researchers, pharmaceutical companies, and the FDA reconsider placebo-controlled, relapse prevention studies in schizophrenia.
Dr. Jeffrey Lieberman and colleagues conclude that the time has come to cease the use of placebo in relapse prevention studies and encourage the use of active comparators.
“The effectiveness of combinations of antipsychotic medications remains unclear; reviews of this treatment strategy agree on the need for further investigation,” Dr. T. Scott Stroup and team wrote.
Patients with schizophrenia are often treated with more than one type of psychiatric medication, but a new study suggests that some combinations may be more effective than others.